<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117177</url>
  </required_header>
  <id_info>
    <org_study_id>A2A-004</org_study_id>
    <nct_id>NCT05117177</nct_id>
  </id_info>
  <brief_title>New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer</brief_title>
  <official_title>A Multicenter, Open-Label, Phase I Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Food-Effect of Inupadenant New Formulation in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iTeos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iTeos Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Open-Label, Phase I Clinical Study to assess the Safety, Tolerability,&#xD;
      Pharmacokinetics and Food-Effect of Inupadenant New Formulation in Participants with Advanced&#xD;
      Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Arm A sequential dose escalation Arm B randomized crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose-Limiting Toxicities (DLTs) in patients with advanced solid tumors receiving inupadenant</measure>
    <time_frame>During the DLT evaluation period that is cycle 1 (each cycle is 4 weeks)</time_frame>
    <description>Incidence of adverse events (AEs), serious adverse events (SAEs), DLTs, AEs leading to discontinuation, deaths, electrocardiogram (ECG) abnormalities, and clinically significant laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs in patients receiving inupadenant</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>To assess safety and tolerability as measured by incidence and severity of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of inupadenant vs. time profiles</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Determined by inspection of the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Determined by inspection of the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Determined by inspection of the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Determined by inspection of the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration half-life (T-HALF)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Determined by inspection of the concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Assessment of preliminary efficacy of inupadenant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of food on the exposure to inupadenant will be investigated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inupadenant</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part 1a</arm_group_label>
    <arm_group_label>Part 1b</arm_group_label>
    <other_name>EOS100850</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding participation in the Trial, please refer to your physician&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Women and men â‰¥18 years of age with Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status of 0 or 1&#xD;
&#xD;
          -  Subject with histologically or cytologically confirmed advanced solid tumor for whom&#xD;
             no standard treatment is further available.&#xD;
&#xD;
          -  At least 4 weeks since any previous treatment for cancer&#xD;
&#xD;
          -  Subject must consent to pretreatment and on treatment tumor biopsies&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary brain tumors or primary tumors with central nervous system&#xD;
             metastases as only location of disease. Controlled brain metastases are permitted&#xD;
&#xD;
          -  Participants with second/other active cancers requiring current treatment&#xD;
&#xD;
          -  Uncontrolled/significant heart disease&#xD;
&#xD;
          -  Known History of chronic hepatitis, Positive test for Hepatitis B virus surface&#xD;
             antigen or - - Hepatitis C antibody (except participants with liver cancer) or Human&#xD;
             Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)&#xD;
&#xD;
          -  Active/uncontrolled autoimmune disease&#xD;
&#xD;
          -  Active infection Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Machiels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires San Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erol AB Wiegert, MD, PhD</last_name>
    <phone>+49 1759369704</phone>
    <email>info@iteostherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Hanot Mambres, PhD</last_name>
    <email>info@iteostherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Buisseret, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Machiels, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Rottey, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan DeBono, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

